Evaluating HRD Status for Better Ovarian Cancer Treatment

Non-Randomized, Open-Label, Prospective Phase II Trial to Better Characterize the Status of HRD Leading to a Benefit From Olaparib in Combination With Bevacizumab in Patients With Advanced FIGO Stage III-IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First-Line Treatment

This study is testing two different tests to see which one better identifies ovarian cancer patients who can benefit from a combination of two drugs, olaparib and bevacizumab, as a first treatment option.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: Vall d'Hebron Institute of Oncology (Academic / other)
• Drugs / interventions: bevacizumab, chemotherapy
• Locations: 1 site (Barcelona)
• Trial ID: NCT06377267 on ClinicalTrials.gov

What this trial studies

This phase II trial aims to improve the identification of ovarian cancer patients who would benefit from the combination of olaparib and bevacizumab as a first-line maintenance therapy. It will compare the effectiveness of two tests, the VHIO-CARD-300 and SOPHiA DDM™ Dx HRD Solution, in determining homologous recombination deficiency (HRD) status in patients with advanced ovarian cancer. Participants who test HRD-positive will receive the drug combination, while others will receive standard care with bevacizumab alone. The study will assess treatment efficacy, safety, and tolerability over a minimum follow-up period of 30 months.

Who should consider this trial

Good fit: Ideal candidates include patients with newly diagnosed high-grade serous or endometrioid ovarian cancer at advanced stages who have completed first-line platinum-taxane chemotherapy.

Not a fit: Patients with non-serous or non-endometrioid ovarian cancer or those who have not completed the required chemotherapy regimen may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with advanced ovarian cancer.

How similar studies have performed: Other studies have shown promise in using HRD status to guide treatment decisions, but this specific approach is novel.

Eligibility criteria

Inclusion Criteria:

1. Patient with newly diagnosed high- grade serous or endometrioid Ovarian cancer, primary peritoneal cancer and/or fallopian-tube cancer. I-3-3 At an advanced stage: FIGO stage IIIB, IIIC, or IV of the 1988 FIGO classification (see appendix 1).
2. Patient who has completed prior to enrollment first line platinum-taxane chemotherapy:

   1. Platinum-taxane based regimen must have consisted of
   2. minimum of 6 treatment cycles and a maximum of 8. However, if platinum-based therapy must be discontinued early as a result of non-hematological toxicityspecificallyrelated to the platinum regimen, (i.e. neurotoxicity, hypersensitivity etc.), patient must have received a minimum of 4 cycles of the platinum regimen.
   3. Patient must have received prior to enrollment a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of platinum-based chemotherapy. Only in case of interval debulking surgery, it is allowed to realize only 2 cycles of bevacizumab in combination with the last 3 cycles of platinum-based chemotherapy.
3. Patient must be prior to enrollment without evidence of disease (NED) or in complete response (CR) or partial response (PR) from the first line treatment. There should be no clinical evidence of disease progression (physical exam, imagery, CA 125) throughout he first line treatment and prior to study enrollment.
4. Patient must be randomized at least 4 weeks and no more than 8 weeks after her last dose of chemotherapy (last dose is the day of the last infusion) and all major toxicities from theprevious chemotherapy must have resolved to CTCAE grade 1 or better (except alopecia and peripheral neuropathy).
5. Patient must have normal organ and bone marrow function:
6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (see appendix 3)
7. Formalin fixed, paraffin embedded (FFPE) tumor sample from the primary cancer must be available for central BRCA testing and test result must be available for stratification.

Exclusion Criteria:

1. Non-epithelial origin of the ovary, the fallopian tube or the peritoneum (i.e. germ cell tumors).
2. Ovarian tumors of low malignant potential (e.g. borderline tumors) or mucinous carcinoma.
3. Other malignancy within the last 5 years except:
4. Patient with myelodysplastic syndrome/acute myeloid leukemia history.
5. Major surgery within 4 weeks of starting study treatment and patient must have recovered from any effects of any major surgery.
6. Any previous treatment with PARP inhibitor, including olaparib.
7. Concomitant use of known potent CYP3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin and nelfinavir.
8. Prior history of hypertensive crisis (CTC-AE grade 4) or hypertensive encephalopathy.
9. Clinically significant (e.g. active) cardiovascular disease, including:

   1. Myocardial infarction or unstable angina within ≤ 6 months of enrollment,
   2. New York Heart Association (NYHA) ≥ grade 2 congestive heart failure (CHF) (see appendix 5).
   3. Poorly controlled cardiac arrhythmia despite medication (patient with rate controlled atrial fibrillation are eligible), or any clinically significant abnormal finding on resting ECG,
   4. Peripheral vascular disease grade ≥ 3 (e.g. symptomatic and interfering with activities of daily living \[ADL\] requiring repair or revision)
10. Previous Cerebro-Vascular Accident (CVA), Transient Ischemic Attack (TIA) or Sub-Arachnoids Hemorrhage (SAH) within 6 months prior to enrollment.
11. History or evidence of hemorrhagic disorders within 6 months prior to enrollment.
12. History or clinical suspicion of brain metastases or spinal cord compression.
13. Significant traumatic injury during 4 weeks prior to enrollment.
14. Non-healing wound, active ulcer or bone fracture.
15. History of VEGF therapy related abdominal fistula or gastrointestinal perforation or active gastrointestinal bleeding within 6 months prior to the first study treatment.
16. Current, clinically relevant bowel obstruction, including sub-occlusive disease, related to underlying disease.
17. Patient with evidence of abdominal free air not explained by paracentesis or recent surgical procedure.

Where this trial is running

Barcelona

• Vall d'Hebron Institute of Oncology — Barcelona, Spain (Recruiting)

Study contacts

• Principal investigator: Ana Oaknin — Vall d'Hebron Institute of Oncology
• Study coordinator: Ana Oaknin

Conditions Ovarian Cancer; HRD status